I agree Stone. Introducing new technology to the medical community is often a hard sell. The number of centres (and surgeons) using cardiocel in these early days is impressive.
Looking back to October 2012 (and the announcement in paper that brought the success of cardiocel to my attention and saw the beginning of this crazy journey for me), in just two short years, the company has progressed from reporting a successful ( and somewhat revolutional) new medical product to establishing a sizable (and apparently growing) customer base, with encouraging sales figures (and potential re ordering), across two overseas highly regulated marketplaces.
If the view of the targets we have not made is not to our liking, we can always look at the achievements that have been in a relatively short time.
Just my two cents worth.
16 Centres Ordering in Europe, page-20
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |